The autoinjector will be free for insured patients and those whose annual income is less than $100,000.
Eli Lilly and Express Scripts are seeking to avoid potential bad press over high insulin prices.
A more affordable competitor to Mylan's MYL EpiPen is set to enter the market earlier than expected, and will likely pose a threat to the autoinjector's dominance in the space.
A competitor to Mylan's MYL autoinjector, EpiPen, will hit the market sooner than expected thanks to a private pharmaceutical company, Kaleo Pharmaceuticals.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.